MYGN Nov 2024 25.000 call
| Previous Close | 1.2500 |
| Open | 1.2500 |
| Bid | 2.3500 |
| Ask | 4.0000 |
| Strike | 25.00 |
| Expire Date | 2024-11-15 |
| Day's Range | 1.2500 - 1.2500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 11 |
GlobeNewswireMyriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
Molecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and CollaboratorsSALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies at the 2024 ASCO Annual Meeting. Three studies led by Myriad focus on breast cancer risk assessment, and four additional studies will be shared by collaborators that wi
- GlobeNewswire
New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
Myriad’s Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1 SALT LAKE CITY, May 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that JCO Precision Oncology has published a study showing a clinical cell-cycle risk (CCR) score can accurately predict the benefit of adding androgen deprivation therapy (ADT) to radiation therapy (RT) in men with
GuruFocus.comInsider Sale: President and CEO Paul Diaz Sells 227,844 Shares of Myriad Genetics Inc (MYGN)
On May 15, 2024, Paul Diaz, President and Chief Executive Officer of Myriad Genetics Inc (NASDAQ:MYGN), executed a significant transaction by selling 227,844 shares of the company.
